Catena Biosciences
YC S21San Francisco, US · Founded 2020 · 7 employees · 3 known investors
Catena develops a conjugation platform for antibody-drug conjugates (ADCs) and multi-payload conjugates used in oncology for solid tumors. The company's technology enables therapeutic structures that deliver dual payloads to cancer targets.
Founders & leadership· Y Combinator alumni (S21)
Marco LobbainFounder
Matthew FrancisinFounder
Investors · 3
In the news
- CatenaBio Secures $2.35M in Seed Funding to Accelerate Breakthrough Therapeutics Development | SignalBasetrysignalbase.com · 2024
- CatenaBio - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2024
- 19 Dec - Catena Bioscienceseqtfoundation.com · 2023
- Social Impact Capital - Catena Biosciencessocial-impact-capital.com · 2021
- Berkeley startup aims to be a game changer in autoimmune disease therapy | Berkeley Newsnews.berkeley.edu · 2021